Table 1. Clinical trials evaluating the combinations of capecitabine and/or fluorouracil with oxaliplatin in advanced pancreatic ductal adenocarcinoma.
| Author | Year | N | 1st or 2nd line treatment | 5FU or capecitabine | ORR (%) | DCR (%) | mPFS/TTP (months) | mOS (months) |
|---|---|---|---|---|---|---|---|---|
| Ducreux (6) | 2004 | 31 | 1st | 5FU | 10 | NA | 4.2 | 9.0 |
| Tsavaris (7) | 2005 | 30 | 1st | 5FU | 23.3 | 53.3 | 5.5 | 6.3 |
| Ghosn (8) | 2007 | 30 | 1st | 5FU | 27.6 | 62 | 4 | 7.5 |
| Boeck (9) | 2008 | 61 | 1st | Capecitabine | 13 | 49 | 4.2 | 8.1 |
| Mitry (10) | 2006 | 18 | 2nd | 5FU | 0 | 17 | 0.9 | 4.9 |
| Xiong (11) | 2008 | 41 | 2nd | Capecitabine | 3 | 28 | 2.5 | 5.8 |
| Novarino (12) | 2009 | 23 | 2nd | 5FU | 0 | 23.5 | 2.9 | 4.3 |
| Yoo (13) | 2009 | 30 | 2nd | 5FU | 7 | 17 | 1.5 | 3.7 |
| Pelzer (14) | 2011 | 46 | 2nd | 5FU | 0 | NA | NA | 4.8 |
| Berk (15) | 2012 | 85 | 2nd | 5FU and capecitabine | 18 | 59 | 4 | 5.3 |
| El-Hadaad (16) | 2013 | 30 | 2nd | 5FU | 6.7 | 26.7 | 3.3 | 5.5 |
| Oettle (17) | 2014 | 77 | 2nd | 5FU | NA | NA | 2.9 | 5.9 |
ORR, overall response rate (% partial plus complete response per RECIST); DCR, disease control rate (ORR plus % stable disease); mPFS, median progression free survival; mTTP, median time to progression; mOS, median overall survival. Results reported in weeks converted to months using 1 week, 7 days and 4 weeks, 1 month.